Open Terminal →

Analyses / PATH

PATH UiPath Inc As of Nov 18, 2026
$12.39

Mid-cap software name, down 5.7% on the session and near its day low. Growth is intact, but insider selling and thin margin data keep the read mixed.

Setup: Mixed recovery watch Confidence: low Horizon: 3m Risk: medium-high Category: Mid cap
🔒 Trade Plan — entry · target · stop
Entry Zone
$•••–•••
Target
$•••
Stop Loss
$•••
Risk / Reward
•.• : 1
Unlock the exact levels — free →

A free account reveals PATH's entry zone, price target & stop loss. Full 1-week to 1-year price forecasts are included with Pro.

The Thesis

▲ Bull Case

In a bull scenario, revenue growth of 15% (5-year 21.5%) and an 83% gross margin keep the software growth thesis intact. Trailing P/E of 17.8 and price-to-free-cash-flow of 18.3 are not stretched for that growth. The stock sits about 30% up its 52-week range, leaving room to recover toward the prior close of 13.14 and the day high of 13.09. Operating margin expansion from 3.5% would strengthen the case.

▼ Bear Case

In a bear scenario, the stock fell 5.7% and closed at its day low. Insiders recorded 78 sell transactions (42.8M shares) against 17 buys (33.7M shares). Forward P/E of 22.9 sits above trailing 17.8, which may signal lower expected earnings. Operating margin of 3.5% leaves little cushion, and EV/EBITDA of 101x looks stretched. A break below the 52-week low of 9.20 would be a notable technical failure.

Valuation

FAIRLY PRICED — score 50/100

Trailing multiples look moderate, but forward P/E is higher and EV/EBITDA is unreliable given the margin data gap.

Technical Levels

Support · $12.39 (Current price and day low) · $12.96 (Session open) · $9.20 (52-week low)

Resistance · $13.09 (Day high) · $13.14 (Prior close) · $19.84 (52-week high)

RSI: Unavailable in provider payload

Financial Health

Score 60/100. Liquidity ratios are solid. Leverage and coverage data are missing, so the balance sheet read is incomplete.

Catalysts

Gemini Healthcare tie-up question raised in recent coverageRecent news; timing not specifiedunclear
AI cost positioning versus software peersRecent coveragemedium
Next earnings report dateNot in provider payloadhigh

Risk Flags

Provider coverage is thin: RSI, ROE, ROIC, debt-to-equity, interest coverage and FCF per share are null.
Net margin (17.5%) and operating margin (3.5%) diverge sharply; verify before relying on either.
EV/EBITDA of 101x conflicts with the low operating margin; treat as unreliable until reconciled.
Insider activity is net selling: 78 sells vs 17 buys, 42.8M shares sold vs 33.7M bought.
Forward P/E (22.9) is above trailing P/E (17.8), which may point to lower expected earnings.
Stock is down 5.7% on the session and trades at its day low of 12.39.

See PATH's full trade plan — free

Create a free account to unlock the exact entry, target, and stop — plus run live analysis on any of 5,000+ tickers. No card required.

Unlock PATH free →

Recent News

More Analyses

PATH FAQ

Is PATH a buy right now?

UiPath Inc's current read is a Mixed recovery watch setup with low confidence over a 3m horizon. Valuation: FAIRLY PRICED. See the full bull and bear case above, or run a live analysis for the exact entry, target and stop.

Is PATH overvalued?

FAIRLY PRICED (valuation score 50/100). Trailing multiples look moderate, but forward P/E is higher and EV/EBITDA is unreliable given the margin data gap.

What are the risks of buying PATH?

In a bear scenario, the stock fell 5.7% and closed at its day low. Insiders recorded 78 sell transactions (42.8M shares) against 17 buys (33.7M shares). Forward P/E of 22.9 sits above trailing 17.8, which may signal lower expected earnings. Operating margin of 3.5% leaves little cushion, and EV/EBITDA of 101x looks stretched. A break below the 52-week low of 9.20 would be a notable technical failure.